EUVIMEDEUVIMED entdecken
Scoping Review

Larval Therapy for Chronic Wounds: Scoping Review with ☸️SAIMSARA

SAIMSARA Journal · 02.05.2026 · 1 (1)

DOI: 10.62487/saimsara9407ba6d ↗

Kurz gefasst

Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 02.05.2026. Die Arbeit nennt 97 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To synthesize current evidence regarding the clinical efficacy, biological mechanisms, and patient-centered outcomes of larval therapy in the management of acute and chronic wounds across human and animal models. The review utilises 93 original studies with 11977 total participants (topic deduplicated ΣN). Across the mapped evidence, larval therapy emerged most consistently as a rapid biological debridement strategy, with reported signals including a 92.3% wound-healing rate in post-revascularization ischemic wounds versus 18.2% with vacuum-assisted closure at one month, median free-range debridement of 4 days versus 9 days for bagged larvae in Wagner grade 2 diabetic ulcers, and 86–100% debridement success in heterogeneous chronic-wound cohorts. The dominant topic clusters indicate that this debridement advantage is mechanistically supported by serine proteases and antimicrobial peptides such as Sarconesin and Lucifensin, yet does not consistently translate into improved complete healing compared with hydrogel or compression-based care over follow-up. Recurrent signals around increased ulcer-related pain, particularly in vascular-etiology wounds, and around clinician disgust and patient acceptability highlight tolerability and implementation as parallel constraints to clinical efficacy. The mapped evidence is limited by small human samples and heterogeneous wound types, so these patterns should be read as scoping-level signals rather than confirmatory effects. Practically, the synthesis supports a role for larval therapy as a targeted debridement option in sloughy, infected, complex, high-risk, or ischemic wounds where surgical debridement is constrained, provided that pain management and hygiene safeguards are in place. Future research should prioritize adequately powered randomized trials that link accelerated debridement to long-term closure, alongside standardization of larval density and dwell time and continued development of recombinant enzyme, lyophilized extract, and transgenic growth-factor formulations to address tolerability and acceptability gaps.

Zitieren

APA

(2026). Larval Therapy for Chronic Wounds: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsara9407ba6d

Vancouver

Larval Therapy for Chronic Wounds: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsara9407ba6d

BibTeX
@article{euvimed2026,
  title = {Larval Therapy for Chronic Wounds: Scoping Review with ☸️SAIMSARA},
  journal = {SAIMSARA Journal},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.62487/saimsara9407ba6d}
}
Kostenlos starten →